GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Co-Diagnostics CODX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.32

+24.22%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Co-Diagnostics

From its filings with the US Securities and Exchange Commission

SEC filings

Co-Diagnostics is based in Salt Lake City, Utah and is incorporated in Utah. Its shares trade on Nasdaq under the ticker CODX. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $622,489 and a net loss of $46.9m. At that date it held total assets of $24.7m and shareholders' equity of $20.6m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
12 Jul 2017
Employees
115
Head office
2401 S FOOTHILL DRIVE, SALT LAKE CITY, UT, 84109
Incorporated in
UT
Classification
Surgical & Medical Instruments & Apparatus
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Dwight EganChairman of the Board, President, Chief Executive Officer, since 2013$716,917
  • Mr. Richard AbbottPresident$424,866
  • Mr. Brian BrownChief Financial Officer, Company Secretary$578,083
  • Dr. Eugene DurenardIndependent Director$222,100
  • Mr. Edward MurphyIndependent Director$222,100
  • Mr. James NelsonIndependent Director$222,100
  • Mr. Richard SerbinIndependent Director$222,100

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
29
Environment
34
Social
8
Governance
44
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Co-Diagnostics Inc's proprietary test design system enables molecular testing for organisms and genetic diseases in Salt Lake City, Utah.
  • The company's reagents are used for diagnostic tests detecting nucleic acid molecules, including deoxyribonucleic acid and ribonucleic acid.
  • Co-Diagnostics Inc's MDx device offers self-contained lab systems for diagnostic equipment from other manufacturers.

Weaknesses

  • Co-Diagnostics Inc has only 115 employees, which constrains its operational capacity.
  • The company's IPO occurred in July 2017, indicating a relatively recent market listing.
  • Co-Diagnostics Inc is headquartered in Salt Lake City, Utah, limiting its geographic reach.

Opportunities

  • Co-Diagnostics Inc can expand its diagnostics technology development in the Health Care sector.
  • The company has the potential to increase sales of its polymerase chain reaction diagnostic tests for diseases and pathogens.
  • Co-Diagnostics Inc can leverage its proprietary reagents for additional diagnostic applications.

Threats

  • Co-Diagnostics Inc faces competition in the Health Care industry for diagnostics technology.
  • The company's reliance on nucleic acid molecule detection may be challenged by emerging technologies.
  • Co-Diagnostics Inc's limited employee count of 115 may hinder its ability to respond to market demands.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.